Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci178446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Manoela Tiago und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, COUP Transcription Factor I, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health (NIH)/National Cancer Institute, American Cancer Society.
Abstract (Originalsprache)
Despite the success of targeted inhibitors in cutaneous melanoma, therapeutic responses are limited by the aged tumor microenvironment and drug-tolerant residual cells. Given the similarities between drug tolerance and cellular dormancy, we studied the dormancy marker, nuclear receptor subfamily 2 group F member 1 (NR2F1), in response to BRAF-V600E inhibitors (BRAFi) plus MEK inhibitors (MEKi) in BRAF-mutant melanoma models. Transcriptomic analysis of melanoma patient samples treated with BRAFi + MEKi showed increased NR2F1. NR2F1 was highly expressed in the drug-tolerant invasive cell state of minimal residual disease in patient-derived and mouse-derived xenografts on BRAFi + MEKi. NR2F1 over-expression was sufficient to reduce BRAFi + MEKi effects on tumor growth in vivo, and cell proliferation, death, and invasion in vitro. Effects were linked to genes involved in mTORC1 signaling. These cells were sensitive to the combination of BRAFi, MEKi plus rapamycin. Melanomas from aged mice, known to exhibit decreased responses to BRAFi + MEKi, displayed higher levels of NR2F1 compared to tumors from young mice. Depleting NR2F1 in an aged mouse melanomas improved the response to targeted therapy. These findings show high NR2F1 expression in ‘invasive-state’ residual cells and that targeting NR2F1-high cells with mTORC1 inhibitors may improve outcomes in patients with melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Clinical Chemistry and Toxicology, University of São Paulo, São Paulo, Brazil.
- Department of Cancer Signaling and Microenvironment, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania, USA.
- Department of Cell Biology, Cancer Dormancy Institute, Montefiore Einstein Comprehensive Cancer Center, Gruss Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- Department of Medical Microbiology, Immunology, and Cell Biology at SIU Medicine, Springfield, Illinois, USA.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Förderung
- NCI NIH HHS
- National Institutes of Health (NIH)/National Cancer Institute
- American Cancer Society
Zitieren
APA
Tiago, M., Purwin, T. J., Stefanski, C. D., da Silva, R. O., Fane, M. E., Chhabra, Y., Haj, J. I., Teh, J. L., Kadamb, R., Cai, W., Rosenbaum, S. R., Chua, V., Hacohen, N., Davies, M. A., Villanueva, J., Chervoneva, I., Weeraratna, A. T., Erkes, D. A., Capparelli, C., …, & Aplin, A. E. (2025). Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci178446
Vancouver
Tiago M, Purwin TJ, Stefanski CD, da Silva RO, Fane ME, Chhabra Y, et al. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. Journal of Clinical Investigation. 2025. doi:10.1172/jci178446
BibTeX
@article{Tiago2025,
author = {Tiago, Manoela and Purwin, Timothy J and Stefanski, Casey D and da Silva, Renaira Oliveira and Fane, Mitchell E and Chhabra, Yash and Haj, Jelan I and Teh, Jessica Lf and Kadamb, Rama and Cai, Weijia and Rosenbaum, Sheera R and Chua, Vivian and Hacohen, Nir and Davies, Michael A and Villanueva, Jessie and Chervoneva, Inna and Weeraratna, Ashani T and Erkes, Dan A and Capparelli, Claudia and Aguirre-Ghiso, Julio A and Aplin, Andrew E},
title = {Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci178446}
}
EUVIMED